Clinical Trial Update: A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab [Phase 2]

View source ↗

Summary

Phase 2 long-term safety extension study for crenezumab in mild to moderate Alzheimer's disease completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Crenezumab

Snippet

Sponsor: Genentech, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-02-12